Adviser Appointments

RNS Number : 2273A

Nuformix PLC

01 February 2022

 

1 February 2022

Nuformix plc

("Nuformix" or the "Company")

Adviser Appointments

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Stanford Capital Partners Limited as Financial Adviser and Broker to the Company, with immediate effect. 

Additionally, IFC Advisory Limited have been appointed as the Company's new financial public relations and investor relations adviser with immediate effect.

Enquiries:

Nuformix plc
Dr Alastair Riddell, Executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
John Howes (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.

 

END

 

 

APPBKDBBCBKDQDN